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Abstract
: A previous systematic review reported that topical NSAIDs were effective in relieving pain in
chronic conditions like osteoarthritis and tendinitis. More trials, a better understanding of trial
quality and bias, and a reclassification of certain drugs necessitate a new review.
Methods: Studies were identified by searching electronic databases, and writing to manufacturers.
We identified randomised, double blind trials comparing topical NSAID with either placebo or
another active treatment, in adults with chronic pain. The primary outcome was a reduction in pain
of approximately 50% at two weeks, and secondary outcomes were local and systemic adverse
events and adverse event-related withdrawals. Relative benefit and number-needed-to-treat
(NNT), and relative harm and number-needed-to-harm (NNH) were calculated, and the effects of
trial quality, validity and size, outcome reported, and condition treated, were examined by
sensitivity analyses.
Results: Twelve new trials were added to 13 trials from a previous review. Fourteen double blind
placebo-controlled trials had information from almost 1,500 patients. Topical NSAID was
significantly better than placebo with relative benefit 1.9 (95% confidence interval 1.7 to 2.2), NNT
4.6 (95% confidence interval 3.8 to 5.9). Results were not affected by trial quality, validity or size,
outcome reported, or condition treated. Three trials with 764 patients comparing a topical with
an oral NSAID found no difference in efficacy. Local adverse events (6%), systemic adverse events
(3%), or the numbers withdrawing due to an adverse event were the same for topical NSAID and
placebo.
Conclusions:  Topical NSAIDs were effective and safe in treating chronic musculoskeletal
conditions for two weeks. Larger and longer trials are necessary to fully elucidate the place of
topical NSAIDs in clinical practice.
Background
A systematic review of topical NSAIDs reported that they
were effective for relieving pain in both acute and chronic
conditions [1]. Number-needed-to-treat (NNT), the
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number of patients that need to be treated for one to ben-
efit from a particular drug, who would not have benefited
from placebo, was used to estimate efficacy. In chronic
conditions, NNT for topical NSAIDs at two weeks was 3.1
(2.7 to 3.8).
There are three reasons why an updated review of topical
NSAIDs in chronic pain is needed. First, we have a better
appreciation of factors that can introduce bias [2-4], and
would not now accept trials that were not double blind, or
were very small. Second, topical salicylate and benzydam-
ine are no longer classed as topical NSAIDs [5]. Thirdly,
there are now more trials. We believed that updating the
review would improve efficacy estimates for topical
NSAIDs, with a prior intent to determine efficacy for indi-
vidual drugs.
Methods
Searching
Relevant studies were sought regardless of publication
language, type, date or status. Studies included in the pre-
vious review were considered for inclusion, and the
Cochrane Library, MEDLINE and PreMedline, EMBASE
and PubMed, were searched for relevant studies published
since the last review, for the years 1996 to April 2003. The
search strategy included "application: topical" together
with "cream", "gel" etc, together with generic names of
NSAIDs, and proprietary preparations of topical treat-
ment in which the principal active ingredient was an
NSAID [6,7] (additional file 1:search strategy). Reference
lists of retrieved articles were also searched. We wrote to
20 pharmaceutical companies in the UK, 66 in continen-
tal Europe, and two in North America, known to manu-
facture topical NSAIDs, asking if they could supply
papers.
Selection
We identified reports of randomised, double blind, active
or placebo-controlled trials in which treatments were
given to adult patients with moderate to severe chronic
pain resulting from musculoskeletal or other painful dis-
orders. We excluded treatments for mouth or eye diseases.
At least ten patients had to be randomised to a treatment
group and application of treatment had to be at least once
daily. Outcomes closest to two weeks (but at least seven
days) were extracted. Longer outcomes were also accepted
when available.
Quality and validity assessment
Trial quality was assessed using a validated three-item
scale with a maximum quality score of five [8]. Included
studies had to score at least two points, one for randomi-
sation and one for blinding. A sixteen-point scale was
used to assess trial validity [9]. Quality and validity assess-
ments were made independently by at least two reviewers
and verified by one other reviewer. Disputes were settled
by discussion between all reviewers.
Outcomes
We defined our own outcome of clinical success, repre-
senting approximately a 50% reduction in pain [1]. This
was either the number of patients with a "good" or "excel-
lent" global assessment of treatment, or "none" or "slight"
pain on rest or movement (or comparable wording)
measured on a categorical scale. A hierarchy of outcomes
was used to extract efficacy information [1], shown below
in order of preference:
1) number of patients with a 50% or more reduction in
pain
2) patient reported global assessment of treatment
3) pain on movement
4) pain on rest or spontaneous pain
5) physician or investigator global assessment of
treatment
In addition, the number of patients showing undefined
"improvement" was also accepted. All of these outcomes
were grouped together as a "success", and categories 1–4
were used as preferred outcomes in the sensitivity
analysis.
Secondary outcomes were extracted from included papers
that reported them. These were the number of patients (i)
reporting one or more local adverse event (itching, sting-
ing, rash), (ii) reporting one or more systemic adverse
event (iii) withdrawing from trials due to adverse events.
Quantitative data synthesis
The number of patients randomised into each treatment
group (intention to treat) was used in the efficacy analysis.
Information was pooled for the number of patients in
each trial approximating at least 50% pain relief, or simi-
lar measure, for both topical NSAID and control. These
were used to calculate NNT with a 95% confidence inter-
val (CI) [10]. Relative benefit and relative risk estimates
with 95% CIs were calculated using the fixed effects model
[11]. A statistically significant benefit of topical NSAID
over control was assumed when the lower limit of the
95% confidence interval (CI) of the relative benefit was
greater than one. A statistically significant benefit of con-
trol over active treatment was assumed when the upper
limit of the 95% CI was less than one. Homogeneity of tri-
als was assessed visually [12-14]. Number-needed-to-
harm (NNH) and relative risk were calculated in the same
way as for NNTs and relative benefit. All calculations wereBMC Musculoskeletal Disorders 2004, 5:28 http://www.biomedcentral.com/1471-2474/5/28
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performed using Microsoft Excel X for the Macintosh and
RevMan 4.2. In sensitivity analyses the z test was used
[15]. QUOROM guidelines were followed [16].
Sensitivity analysis
Our prior intention was to perform sensitivity analyses on
pooled outcomes using the z test [15] for quality score (2
versus 3 or more), validity score (8 or less versus 9 or
more), trial size (less than 40 patients per group versus
more than 40 patients per group), reported outcome
(higher versus lower preference), drug, and condition
treated (knee osteoarthritis versus other musculoskeletal).
At least three studies had to be available in each category
before information was pooled.
Results
Study characteristics
Ten out of the 20 UK companies, and two out of the 66
continental European companies replied to our request
for studies. Only three companies supplied useful mate-
rial, either published studies or bibliographies. None pro-
vided unpublished material.
Searches identified 60 target papers, but 35 were excluded;
23 studies failed to meet the inclusion criteria and 12 had
no useable data. Twenty-four of these 60 target papers
were included in the previous review. We included 13 of
those in this review, and excluded 11; seven were not dou-
ble blind, two compared a salicylate with placebo or oral
analgesics, one did not have daily application, and one
had insufficient data (additional file 2: excluded studies,
additional file 3: QUOROM flow diagram).
Twenty-five trials therefore met the selection criteria, 12 of
which were additional trials. Fifteen trials had only pla-
cebo controls [17-31], seven only active controls [32-38],
and three had both placebo and active controls [39-41].
Of the 10 active controlled trials, four compared a topical
NSAID with a different topical NSAID, three compared a
topical NSAID with a different oral NSAID, and one each
compared a topical NSAID with a homeopathic gel, a top-
ical rubefacient, and topical trinitroglycerin (GTN).
Details of all included studies with outcomes and quality
and validity scores are in additional files 4 (Outcome
details of placebo-controlled trials) and additional files 5
(Outcome details of active-controlled trials).
Patients were generally over 40 years old, predominantly
with musculoskeletal disorders, and with baseline pain of
moderate to severe intensity. Fourteen studies examined
general musculoskeletal conditions, and eleven examined
osteoarthritis (9 studies of the knee, one of finger joints,
and one of mixed sites). Five studies in osteoarthritis spec-
ified use of a standard scale (ACR, Kellgren and Lawrence,
ISK) to assess the severity of disease, four specified that the
disease was radiologically confirmed, one specified that
patients had "well documented mild osteoarthritis", and
one made no statement.
Quality scores were high, with 16/18 placebo controlled
and 9/10 active controlled trials scoring 3 or more points
out of a maximum of 5. Validity scores were also high,
with 14/18 placebo controlled and 8/10 active controlled
trials scoring 9 or more out of a maximum of 16 (addi-
tional files 4 and 5).
Placebo controlled trials
Dichotomous information was available to pool from 14
placebo controlled trials for efficacy, from 16 placebo
controlled trials for local adverse events, 17 placebo con-
trolled trials for systemic adverse events, and from 11 pla-
cebo controlled trials for adverse event related
withdrawals.
Efficacy
Fourteen trials (1,502 patients) provided data on efficacy.
Topical NSAIDs were significantly better than placebo
(Table 1). The mean placebo response rate was 26% rang-
ing from 7% to 78%. The mean treatment response rate
was 48% ranging from 2% to 90% (Figure 1). The NNT
was 4.6 (95% CI 3.8 to 5.9) for one patient to experience
improvement in chronic musculoskeletal pain at two
weeks with topical NSAIDs, compared with placebo.
Sensitivity analyses (Table 1) showed no significantly
greater effect for low quality trials (quality score 2/5) com-
pared with higher quality trials (quality score 3–5/5) (z =
1.69, p = 0.091). There was no significant difference for
smaller versus larger trials using 50 patients per group
(median group size for topical NSAID was 49) as a cut off
(z = 0.40, p = 0.69), for preferred outcomes versus lower
preference outcomes (physician determined or general
improvement) (z = 1.56, p = 0.12), or for patients with
knee osteoarthritis compared with other musculoskeletal
conditions (z = 0.99, p = 0.32) (Figure 2). The 10 trials
with both a quality score of 3/5 or greater and a validity
score of 9/16 or greater had an NNT of 4.4 (95% CI 3.6 to
5.6). There were insufficient data to allow comparisons of
efficacy between different NSAIDs.
Harm
All 18 placebo controlled trials (2,032 patients) provided
some information on adverse events (Table 2). There was
no statistically significant difference between topical
NSAID and topical placebo for the number of patients
experiencing local adverse events (6%), systemic adverse
events (3%), or the number withdrawing due to an
adverse event (1%). With topical NSAID or topical pla-
cebo, local adverse events were usually described as rash,
itching or stinging, and were predominantly mild.BMC Musculoskeletal Disorders 2004, 5:28 http://www.biomedcentral.com/1471-2474/5/28
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Active controlled trials
Efficacy
There was sufficient information to pool results only from
the three trials comparing a topical NSAID with an oral
NSAID in patients with osteoarthritis of the knee or finger
joints. One trial [34] compared piroxicam 0.5% gel with
oral ibuprofen 1200 mg daily, another [38] compared
diclofenac 1% gel with oral ibuprofen 1200 mg daily, and
the third [41] compared eltenac 1% gel with oral
diclofenac 100 mg daily. In these trials, with 764 patients,
37% had a successful outcome both with topical NSAID
and oral NSAID. There was no statistically significant dif-
ference (relative risk 1.1; 95% CI 0.9 to 1.3). The other
seven studies used different topical preparations and dif-
ferent comparators in small trials (additional file 5: Out-
come details of active-controlled trials).
Harm
Eight of the active controlled trials (1,461 patients) pro-
vided some information on adverse events (Table 2). In
two active controlled trials comparing topical with oral
NSAID, local adverse events occurred more frequently
(8%) with topical than with oral NSAID (3%). Systemic
adverse events and adverse event withdrawals did not dif-
fer between topical and oral NSAID. No study docu-
mented specific instances of upper gastrointestinal
bleeding or symptomatic ulcers.
Discussion
Patients in these trials all had moderate to severe baseline
pain, and for those with osteoarthritis, disease severity
was generally mild to moderate. Patients with most severe
disease were specifically excluded in several trials because
authors regarded topical NSAID to be inappropriate for
their treatment.
Both the original and this updated review concluded that
topical NSAIDs were effective in chronic conditions.
Table 1: Summary data and sensitivity analyses for placebo controlled trials
Number of Success/total
Trial characteristic Trials Patients Treatment Placebo RB (95% CI) NNT (95% CI)
All trials 14 1502 371/771 193/731 1.9 (1.7 to 2.2) 4.6 (3.8 to 5.9)
Quality and validity
Quality score 3 to 5 11 1312 294/678 144/634 2.0 (1.7 to 2.4) 4.8 (3.9 to 6.4)
Quality score 2 3 190 77/93 49/97 1.6 (1.3 to 2.0) 3.1 (2.2 to 5.1)
Validity score ≥ 9 and quality score ≥ 3 10 1197 247/622 98/575 2.4 (2.0 to 3.0) 4.4 (3.6 to 5.6)
Trial group size
≤ 50 patients 6 343 95/172 54/171 1.8 (1.4 to 2.3) 4.2 (3.0 to 7.4)
> 50 patients 8 1159 276/599 139/560 2.0 (1.7 to 2.3) 4.7 (3.8 to 6.3)
Outcome type
preferred outcomes 8 920 198/462 85/458 2.3 (1.9 to 2.9) 4.1 (3.3 to 5.4)
lower preference outcomes 6 582 173/309 108/273 1.6 (1.4 to 1.9) 6.1 (4.1 to 12)
Condition
knee osteoarthritis 5 567 127/307 58/260 2.0 (1.6 to 2.6) 5.3 (3.8 to 8.6)
other musculoskeletal 9 935 244/464 135/471 1.9 (1.6 to 2.2) 4.2 (3.3 to 5.6)
Topical NSAIDs in chronic musculoskeletal pain Randomised  double-blind studies of topical NSAID compared to topical  placebo for two-week outcome of successful treatment Figure 1
Topical NSAIDs in chronic musculoskeletal pain Randomised 
double-blind studies of topical NSAID compared to topical 
placebo for two-week outcome of successful treatment. 
Inset scale shows size of individual trials.
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However, removing trials of lower quality, and topical
agents that are not now regarded as topical NSAIDs,
increased (worsened) the NNT from 3.1 (95% CI 2.7 to
3.8) to 4.7 (95% CI 3.8 to 5.9) for the outcome of at least
half pain relief at two weeks for all topical NSAIDs com-
pared to placebo. For every four or five patients with
chronic pain treated with topical NSAID, one would ben-
efit who would not have done with placebo. Three trials
comparing topical with oral NSAID found no difference
in efficacy.
Analysis of trials of topical NSAIDs in chronic musculoskeletal pain by condition Figure 2
Analysis of trials of topical NSAIDs in chronic musculoskeletal pain by condition. This Forrest plot was created using RevMan 
4.2. Details of the statistical tests used can be found in the Cochrane Handbook.
Table 2: Placebo contolled trials
Number of Events/total
Type of adverse event Trials Patients Treatment Placebo RR (95% CI)
Local adverse events 15 1734 53/949 48/785 1.0 (0.7 to 1.4)
Systemic adverse events 16 1838 33/1002 14/836 1.7 (0.96 to 2.85)
Withdrawals beacuse of adverse events 10 1225 10/697 7/528 0.9 (0.4 to 2.1)
Active controlled trials: topical vs oral
Number of Events/total
Type of adverse event Trials Patients Treatment Placebo RR (95% CI)
Local adverse events 2 443 19/243 4/118 3.0 (1.1 to 8.5)
Systemic adverse events 3 764 82/408 87/356 0.83 (0.6 to 1.1)
Withdrawals because of adverse events 3 764 19/408 24/356 0.7 (0.4 to 1.3)BMC Musculoskeletal Disorders 2004, 5:28 http://www.biomedcentral.com/1471-2474/5/28
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There are a number of aspects of this review that might
question this demonstration of efficacy. The trials
spanned several decades and retrospective examination
finds fault with them in several respects. Many trials were
small, and small size can allow chance effects to influence
treatment and placebo event rates [4]. Different
preparations were used, with different formulations, con-
centrations of active ingredient, and application sched-
ules. Reported outcomes were not consistent, and a
hierarchy of outcomes had to be constructed. It was inev-
itable that there would be some clinical heterogeneity,
even when similar patients were treated, and when trials
were both randomised and double blind, and of appropri-
ate duration.
We addressed these limitations with pre-planned sensitiv-
ity analyses. Using studies with higher quality and validity
scores, larger size, or higher rather than lower preference
outcomes made no difference. Patients treated for knee
osteoarthritis derived the same degree of pain relief as
those treated for general musculoskeletal conditions. The
evidence was that topical NSAIDs were effective whatever
strategy was used for sensitivity analysis, improving the
robustness of the overall result.
A possible criticism might be that there has been selective
publication of trials showing topical NSAIDs to be effec-
tive, and suppression of trials where there was no differ-
ence between topical NSAID and placebo. Funnel plots do
not reliably detect publication bias [13,14], so we did not
use them or make any adjustment for possible publication
bias [42]. We did approach every company in the world
that we could identify as being involved with topical
NSAID manufacture or sale for any additional unpub-
lished trials, but no more unpublished material was iden-
tified. When unpublished material is found, it often does
not change the relevance of a result [43-45].
It is important to emphasise that both active and placebo
treatments were rubbed on, making any effect of rubbing
equal in both groups. The mean placebo response in the
included trials was 26%, compared with the mean
response of 48% with topical NSAID. The response with
placebo is consistent with that found in acute and chronic
pain with a variety of conditions and endpoints [46].
Local adverse events were reported with equal frequency
for topical NSAID and topical placebo in placebo-control-
led trials, but more often for topical NSAID than oral
NSAID in active controlled trials. There were no differ-
ences between topical NSAID and topical placebo, or top-
ical NSAID and oral NSAID, for systemic adverse events,
or withdrawals due to adverse events. Studies of short
duration will not capture important long-term safety
information, and this may be important for ongoing
applications of gels, creams or sprays in chronic condi-
tions. There is, however, information that indicates that
topical NSAIDs do not cause the gastrointestinal harm
found with oral NSAIDs [47], nor are they associated with
increased renal failure [48].
Clearly there is a body of evidence to support the efficacy
of topical NSAIDs in chronic painful musculoskeletal con-
ditions. Despite removing smaller studies that were not
double blind, and substituting newer, larger trials of
higher quality, topical NSAIDs remained effective, though
the NNT was higher (worse) than originally estimated [1].
More information of high quality is required, to compare
the relative efficacy of topical and oral NSAIDs, and
between different topical NSAIDs.
We are able to compare the evidence for different topical
analgesics in chronic musculoskeletal pain (Table 3). Sys-
tematic reviews of topical salicylate [49] and capsaicin
[50], tell us what is known about those treatments. As
Table 3 shows, topical NSAIDs have been tested in many
more studies, and in four times as many patients as these
other topical analgesics, and have the lowest (best) NNT.
The limitation of this comparison is essentially the same
limitation as with all these reviews, that the included trials
were too short and too small to be sure of the result. Top-
ical NSAIDs have the best evidence for chronic
musculoskeletal pain, supporting the excellent evidence
available in acute painful conditions [51].
Table 3: Comparison of topical analgesics in chronic musculoskeletal pain
Number of Percent success with
Topical analgesic Trials Patients Treatment Placebo NNT (95% CI)
NSAID 14 1502 48 26 4.6 (3.8 to 5.9)
Salicylates 6 429 54 36 5.3 (3.6 to 10)
Capsaicin 3 368 38 25 8.1 (4.6 to 34)BMC Musculoskeletal Disorders 2004, 5:28 http://www.biomedcentral.com/1471-2474/5/28
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